Jordi Muntané

12PUBLICATIONS
39CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersCancer cell biologyPhylogeny and comparative analysis
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Sep 15, 2025
The many ways to inhibit translation by Sorafenib in liver cancer cells.

Laura Contreras, Sara Ricciardi, Stefano Biffo

|Mar 21, 2025
Sorafenib-associated translation reprogramming in hepatocellular carcinoma cells.

Laura Contreras, Alfonso Rodríguez-Gil, Jordi Muntané

|Nov 28, 2024
Zinc-Based Nanoparticles, but Not Silicon-Based Nanoparticles, Accumulate in Mitochondria and Promote Cell Death in Liver Cancer Cells.

Joana C Pieretti, Thaissa L Horne, Natalia García-Villasante

|Sep 09, 2022
miR-200c-3p, miR-222-5p, and miR-512-3p Constitute a Biomarker Signature of Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma.

Patricia de la Cruz-Ojeda, Tobias Schmid, Loreto Boix

|Mar 10, 2022
Broad Transcriptomic Impact of Sorafenib and Its Relation to the Antitumoral Properties in Liver Cancer Cells.

Laura Contreras, Alfonso Rodríguez-Gil, Jordi Muntané

|Mar 04, 2022
Long non-coding RNA H19 as a biomarker for hepatocellular carcinoma.

Ángela Rojas, Antonio Gil-Gómez, Patricia de la Cruz-Ojeda

Pageof 2

Frequent Collaborators

3 joint publications

Jesús de la Cruz

2 joint publications

Laura Contreras

2 joint publications

Alfonso Rodríguez-Gil

1 joint publications

Stefano Biffo